This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

MECHANISM OF ACTION

TARGET INTERLEUKIN 5 (IL-5) WITH NUCALA

Visual showing NUCALA mechanism of action
Visual showing NUCALA mechanism of action
Visual showing NUCALA mechanism of action

The mechanism of action of mepolizumab in EGPA has not been definitively established.
 

PHARMACODYNAMIC EFFECT

Following subcutaneous administration of NUCALA 300 mg every 4 weeks for 52 weeks, in subjects with EGPA:

  • Blood eosinophils were reduced by 83% compared with placebo
  • This magnitude of reduction was observed within 4 weeks of treatment
  • The clinical significance of these data is unknown